Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

Top Management Presentation
Financial Results of FY2017 Q1

DAIICHI SANKYO CO., LTD

Kazunori Hirokawa
Executive Vice President and CFO

July 31, 2017

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information

Agenda

- FY2017 Q1 Financial Results
- Major Management Topics
  - Edoxaban
  - Japan Business
  - Injectafer
  - Business Growth in China
- R&D Update

FY2017 Q1 Financial Results

Overview of FY2017 Q1 Results

(Bn JPY)

	FY2016 Q1 Results	FY2017 Q1 Results	YoY	
Revenue	**241.0**	**239.1**	-0.8%	**-1.9**
Cost of Sales	**77.6**	**80.1**		**+2.5**
SG&A Expenses	**69.5**	**70.8**		**+1.3**
R&D Expenses	**46.6**	**48.0**		**+1.4**
Operating Profit	**47.3**	**40.3**	-14.8%	**-7.0**
Profit before Tax	**45.2**	**42.2**		**-3.0**
Profit attributable to owners of the Company	**30.6**	**29.2**	-4.7%	**-1.4**

Currency Rate	USD/JPY	108.25	111.10	+2.85
	EUR/JPY	122.17	122.19	+0.02

Revenue

Decreased by 1.9 Bn JPY (Decreased by 3.7 Bn JPY excl. forex impact)

(Bn JPY)



Japan

Positive :	Lixiana	+3.9	Nexium	+1.5
	Pralia	+1.4		
	Daiichi Sankyo Espha			+2.0
Negative :	Olmetec	-1.4		
Daiichi Sankyo Healthcare (OTC)				+2.0

Global (excl. Forex Impact)

Daiichi Sankyo, Inc. :	Olmesartan	-16.6
Luitpold :	GE injectables	+3.0
	Injectafer	+1.9
Daiichi Sankyo Europe :	Olmesartan	-5.0
	Lixiana	+3.5

* Forex impact USD: +1.4, ASCA: +0.4

Operating Profit

Decreased by 7.0 Bn JPY
(Decreased by 7.1 Bn JPY excl. forex impact and special items)

(Bn JPY)



Revenue -1.9
incl. forex impact +1.8

Cost of Sales +1.8
Product mix due to impact of olmesartan LOE

Forex impact +1.7
Cost of Sales +0.6
SG&A Expenses +0.6
R&D Expenses +0.5

Positive Factors Negative Factors

Profit Attributable to Owners of the Company

Decreased by 1.4 Bn JPY

(Bn JPY)



Financial Income / Expenses **-3.9**

Improvement of forex gains/ losses

Revenue: Major Business Units (Incl. Forex impact)

(Bn JPY)

	FY2016 Q1 Results	FY2017 Q1 Results	YoY	vs. Forecast (%)
Japan	**123.4**	**130.0**	**+6.6**	**24.3%**
Daiichi Sankyo Healthcare	**14.8**	**16.8**	**+2.0**	**24.4%**
Daiichi Sankyo Inc.	**40.7**	**25.0**	**-15.7**	**40.3%**
Olmesartan	23.2	6.8	-16.4	48.4%
Welchol	10.0	10.1	+0.2	37.5%
Effient	6.0	6.1	+0.1	-
Savaysa	0.3	0.5	+0.2	24.1%
Movantik	0.9	1.3	+0.4	-
Luitpold	**22.0**	**27.6**	**+5.6**	**26.8%**
Venofer	7.4	7.4	+0.0	26.4%
Injectafer	5.9	8.1	+2.1	24.4%
GE injectables	7.4	10.7	+3.3	-
Daiichi Sankyo Europe	**20.4**	**18.5**	**-1.9**	**28.1%**
Olmesartan	14.0	9.0	-5.0	34.5%
Efient	2.3	1.9	-0.4	27.2%
Lixiana	1.4	4.9	+3.5	22.3%
ASCA (Asia, South and Central America)	**17.7**	**19.0**	**+1.2**	**22.6%**

Currency Rate	USD/JPY	108.25	111.10	+2.85
	EUR/JPY	122.17	122.19	+0.02

Revenue: Major Products in Japan

(Bn JPY)

		FY2016 Q1 Results	FY2017 Q1 Results	YoY	vs. Forecast (%)
Nexium	ulcer treatment	**21.0**	**22.6**	**+1.5**	**24.6%**
Memary	Alzheimer's disease treatment	**12.1**	**12.5**	**+0.4**	**23.2%**
Olmetec	antihypertensive agent	**18.3**	**16.8**	**-1.4**	**35.8%**
Lixiana	anticoagulant	**5.5**	**9.4**	**+3.9**	**24.0%**
Loxonin	anti-inflammatory analgesic	**10.3**	**9.6**	**-0.7**	**29.0%**
Tenelia	type 2 diabetes mellitus treatment	**6.7**	**7.6**	**+0.9**	**25.3%**
Pralia	treatment for osteoporosis	**4.1**	**5.5**	**+1.4**	**23.9%**
Rezaltas	antihypertensive agent	**4.7**	**4.5**	**-0.2**	**28.1%**
Ranmark	treatment for bone complications caused by bone metastases from tumors	**3.4**	**3.8**	**+0.4**	**25.1%**
Efient	antiplatelet agent	**2.5**	**3.3**	**+0.8**	**25.4%**
Inavir	anti-influenza treatment	**0.6**	**0.7**	**+0.2**	**5.5%**
Cravit	synthetic antibacterial agent	**3.8**	**3.3**	**-0.4**	**25.4%**
Urief	treatment for dysuria	**3.0**	**2.9**	**-0.1**	**26.3%**
Omnipaque	contrast medium	**3.7**	**3.6**	**-0.0**	**33.1%**
Mevalotin	antihyperlipidemic agent	**2.9**	**2.4**	**-0.5**	**24.5%**

Major Management Topics

Edoxaban Update

Growth in Japan

As of FY2017 Q1, Lixiana increased its sales share to **20.5%**.



Growth in Japan

Lixiana has reached top Rxs share since Mar. 2017 in prescription number of new patients for AF+VTE. The share expanded to **34.2%** in May 2017.



Source : Medi-trend

Growth in Germany and South Korea

Steady uptake of sales share after launch





LCM update

Based on data from ENSURE-AF

- Following the positive opinion of European CHMP*1 for LIXIANA (edoxaban) in patients with NVAF undergoing cardioversion, SmPC of LIXIANA was updated in “Posology and method of administration“.
  - ✓ Approx. 24 % of newly diagnosed AF patients estimated to undergo cardioversion*2.

- The label update provides guidance on LIXIANA use in NVAF patients undergoing cardioversion. Physicians now rely on the guidance and use LIXIANA for such patients with more confident than ever.

	Clinical Setting (Comparator)	Primary Outcome	Presentaion
ENSURE-AF	Cardioversion (enoxaparin/warfarin)	• Stroke, SEE, MI, CV mortality • Major and CRNM bleeding	ESC 2016

*1: Committee for Medicinal Products for Human Use
*2: Nabauer M., et al. *Europace* (2009) 11, 423–434

Japan Business Update

Expansion of Product Portfolio in Japan

Approval for PRALIA for additional indication (July 2017)

- Indications: Inhibition of the progression of bone erosion*1 associated with rheumatoid arthritis
- Denosumab's approval for rheumatoid arthritis is **first in the world**
- **First product** to have both indications for **osteoporosis and rheumatoid arthritis**
  - ✓About 45% of RA patients complicated with osteoporosis*2

Approval for CANALIA combination tablets (July 2017)

- Combination product of Tenelia and Canaglu tablets, two agents for type 2 diabetes mellitus treatments, created by Mitsubishi Tanabe Pharma Corporation
- Marketing by Daiichi Sankyo, and co-promoting with Mitsubishi Tanabe
- **DPP-4 inhibitor/SGLT2 inhibitor combination** drug, **first approval in Japan**

*1: Bone erosion is a radiological term and reflects the fact that imaging is used for detection. Erosions are visible on plain radiographs as breaks and holes in the bone surface.
*2: 2010 Rheumatism White Paper (The Japan Rheumatism Friendship Association)

Expansion of Product Portfolio in Japan

- **Launch of Narurapid and Narusus for cancer pain treatment (June 2017)**
  - Indications: Analgesic for moderate to severe cancer pain
  - Developed as **unapproved drugs and indications with high medical needs in Japan**

- **Strengthen authorized generic (AG) business through Daiichi Sankyo Espha**
  - Launched **telmisartan (original brand name: Micardis)** and its combination products (June 2017)
  - Launch **olmesartan** and **rosuvastatin (original brand name: Crestor)** in September **ahead of** competitors' generics

Injectafer Update

Growth of Injectafer

- **Expanding monthly revenue under the integrated team (Daiichi Sankyo, Inc. and Luitpold) launched in Jan 2017**





*Injectafer is not indicated for patients who are dialysis dependent

Source: IMS National Sales Perspectives May 2017
(includes all US IV Iron sales in all channels including dialysis chains)

Injectafer Life-Cycle Management

Heart Failure : HEART-FID (Phase 3 Study)
Randomized, double-blind, placebo-controlled study for patients in heart failure (HF) with reduced ejection fraction (HFrEF) with iron deficiency (ID)
FDA Agreement of Special Protocol Assessment to conduct a single pivotal study in HF
Enrolling more than 3,000 adults across North America, Australia and New Zealand
Primary composite outcome measure includes: ➢ 12-month rate of death ➢ 12-month number of hospitalizations for worsening HF ➢ 6-month change in 6-minute walk test
Started March 2017; expected completion in 2022

Iron deficiency is a comorbid condition in 50% of HF patients

HF prevalence has increased 5.8 million (2014) Americans ≥20 years of age.

Restless Leg Syndrome (RLS)
A phase 2, randomized, placebo-controlled study, investigators will assess the efficacy and safety of Injectafer for the treatment of RLS in patients with IDA.

Business Growth in China

Establish Efficient Structures and Expand Revenue

- Sales promotion activities of each product by partners through alliance initially started from outside of major cities

To maximize revenue and profit of products

- Partnering has expanded into **major cities** since **April 2016**

<Revenue>

Over 20% growth in FY2017



<Major Alliances>

Products	Alliance Start	Alliance Expansion
Olmetec	2015.12	2016.4
Olmetec HCTZ	2015.12	
Cravit	2015.1	
Asmeton	2013.9	
Mevalotin	2012.7	
Loxonin tablets	2014.2	
Loxonin tape	2016.1	

Enhance Production Capacity for Business Expansion

- **Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. [Beijing Factory]**

  A new manufacturing line for injectable drugs has been activated since Jan. 2017.
  <Cravit IV>

- **Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. [Shanghai Factory]**

  A new facility for solid-form drugs will be activated in FY2018.
  <Olmesartan family, etc.>

R&D Update

Mirogablin: Phase 3 Result and Future Schedule

	Phase 3 studies	Result (primary endpoint*)
US/EU	Fibromyalgia (FM) –E309	Not-achieved
	Fibromyalgia (FM) –E310	Not-achieved
	Fibromyalgia (FM) –E311	Not-achieved
Japan/ Asia	Post-herpetic neuralgia (PHN)	Achieved
	Diabetic peripheral neuropathic pain (DPNP)	TLR by September 2017

*comparison to placebo

Future schedule

- US/EU
  - ✓ Comprehensive analysis including all studies will be conducted to determine NDA strategy after obtaining TLR of DPNP
- Japan/Asia
  - ✓ NDA strategy and timing will be determined after obtaining TLR of DPNP

- Data disclosure at scientific conferences planned in FY2018

Presentation at ASCO 2017

DS-8201（HER2-ADC）

- Progress of ongoing phase 1 study (oral)
- Immune response of DS-8201 (poster)

U3-1402（HER3-ADC）

- Study design of ongoing phase 1/2 study (poster)

2017 ASCO ANNUAL MEETING
Making a Difference in Cancer Care WITH YOU

DS-8201: ASCO 2017 (Oral)



Tumor size reductions were seen in most patients (reduction is bigger when the bar goes down lower than 0%)

DS-8201: ASCO 2017 (Oral)

Daiichi-Sankyo

Confirmed overall response rate (5.4+6.4 mg/kg)

	ORR n (%)	DCR n (%)
Total	39/97 (40.2)	89/97 (91.8)
Breast Cancer	19/45 (42.2)	44/45 (97.8)
BC Prior T-DM1	16/35 (45.7)	35/35 (100.0)
BC Prior T-DM1+Pertuzumab	14/30 (46.7)	30/30 (100.0)
Gastric Cancer	16/36 (44.4)	32/36 (88.9)
GC Prior CPT-11	8/18 (44.4)	17/18 (94.4)

ORR: Overall Response Rate
DCR: Disease Control Rate

Analysis set: Efficacy evaluable patients for confirmed overall response
Data cutoff on 11-May-2017

ORR was 45.7% in BC patients with prior treatment of T-DM1 (Kadcyla)
ORR was 44.4 % in GC patients with prior treatment of CPT-11 (irinotecan)

DS-8201: ASCO 2017 (Oral)

Daiichi-Sankyo

Tumor size: % Change from baseline (5.4 + 6.4 mg/kg)





Analysis set: Efficacy evaluable patients with at least one scan
Data cutoff on 11-May-2017

Tumor reductions confirmed from beginning of treatment and reductions are continuing

DS-8201: ASCO 2017 (Oral)

Daiichi-Sankyo

Response and treatment duration (Breast cancer, 5.4 + 6.4 mg/kg)



PRESENTED AT: ASCO ANNUAL MEETING '17 | #ASCO17

Presented by: Toshihiko Doi

Median PFS has reached 45.4 weeks
Approximately 80% of patients continue treatment with DS-8201

DS-8201: ASCO 2017 (Oral)

Daiichi-Sankyo

Response and treatment duration (Gastric cancer, 5.4 + 6.4 mg/kg)



PRESENTED AT: ASCO ANNUAL MEETING '17 | #ASCO17

Presented by: Toshihiko Doi

Median PFS has reached 27.3 weeks
Approximately 50% of patients continue treatment with DS-8201

DS-8201: ASCO 2017 (Oral)

Daiichi-Sankyo

TEAE, any grade, >20% (No DLT observed)

Preferred Term (N=133)	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)	All (%)
Hematologic					
Platelet count decreased	13.5	9.0	8.3	3.8	34.6
Anaemia	3.0	12.0	14.3	1.5	30.8
Neutrophil count decreased	0.8	9.8	12.0	3.0	25.6
White blood cell count decreased	0.8	12.8	9.0	1.5	24.1
Gastrointestinal disorders					
Nausea	51.9	13.5	1.5	0.0	66.9
Decreased appetite	33.8	20.3	3.8	0.0	57.9
Vomiting	31.6	3.8	1.5	0.0	36.8
Diarrhea	19.5	5.3	0.8	0.0	25.6
Constipation	18.8	3.0	0.0	0.0	21.8
Others					
Alopecia	21.1	6.0	0.0	0.0	27.1
Malaise	18.0	4.5	0.8	0.0	24.1

Any Grade 3/4 – 43.6%

Analysis set: Safety evaluable patients who received at least one dose of DS-8201a
Data cutoff on 11-May-2017

No dose-limiting toxicity (DLT) was seen
Low incidence of grade 4 adverse events

DS-8201: ASCO 2017(Poster)

Daiichi-Sankyo

Presented immune response of DS-8201

Purpose	To analyze MOA of combination benefit of DS-8201 and anti PD-1 antibody by using syngeneic mouse model
Result	When tumor cell was re-challenged to cured mice that were treated with DS-8201, it was rejected. Thus, activation of antitumor immunity was confirmed. • Up-regulated dendritic cell[*1] marker • Up-regulated MHC-Class I[*2] on tumor cells • Up-regulated PD-L1[*3] on tumor cells
Conclusion	This finding suggests that DS-8201 has ability to activate antitumor immunity and may have additional benefit of combining with immune checkpoint inhibitor

Details will be disclosed in scientific journal.

[*1] Dendritic cells are a type of antigen-presenting cell that form an important role in the adaptive immune system

[*2] MHC-Class I deliver short peptides to the cell surface allowing these peptides to be recognized by T cells

[*3] PD-L1 is a protein on tumor cell. When PD-L1 attach to receptors on T cells called PD-1, it inactivate T cells.

U3-1402: ASCO 2017 (Poster)

- Presented Phase 1/2 study design
  - Target population: HER3 positive refractory/metastatic breast cancer
  - Study status:
    - ✓ Cohort 1 (1.6mg/kg): completed without dose-liming toxicity (DLT)
    - ✓ Cohort 2 (3.2mg/kg): dosing continues



Recommended phase 2 dose will be determined through dose escalation and dose finding parts.

DS-8201: Future Schedule

Future data disclosure (Planned)

September 2017

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

HER2 positive solid tumor (eg colon cancer) excluding breast and gastric cancer

December 2017

SAN ANTONIO BREAST CANCER SYMPOSIUM®

HER2 positive and HER2 low breast cancer

Clinical trial schedule



U3-1402: Future Schedule

Clinical trial schedule



Future milestone

- HER3 positive refractory/metastatic breast cancer TLR: FY2018 Q4
- Start of EGFRm NSCLC study: FY2017 Q3

DS R&D Day 2017

- Date: December 13, 2017 in the afternoon
- Location: Daiichi Sankyo Headquarter Office
- Presenters:
  - Dr. Glenn Gormley (Sr. Executive Officer, Global R&D Head)
  - Dr. Antoine Yver
    (Global Head of Oncology R&D, Head of Daiichi Sankyo Cancer Enterprise)

FY2017 Major R&D Milestone Events

Daiichi-Sankyo

Project	Indication/Study	Q1	Q2	Q3	Q4	FY18-Q1
Denosumab	Rheumatoid arthritis (JP)	Approved				
CL-108	Pain/Opioid-induced nausea and vomiting (US)			Re-submission		
Mirogabalin	Fibromyalgia Phase 3 study (US/EU)	TLR				
	PHN Phase 3 studies（JP/Asia）	TLR				
	DPNP Phase 3 studies（JP/Asia）		TLR			
Pexidartinib	Tenosynovial giant cell tumor Phase 3 study (US/EU)		TLR			Submission
Quizartinib	QuANTUM-R AML 2nd line treatment Phase 3 study (US/EU/Asia)	Interim Analysis				TLR
Esaxerenone (CS-3150)	Hypertension Phase 3 study（JP）			TLR	Submission	
	Diabetic nephropathy Phase 3 study (JP)			Study initiation		
DS-8201	HER2-positive Breast Cancer（T-DM1 resistance or refractory） Phase 2 study (pivotal) (JP/US/EU)		Study initiation			
	HER2-positive Gastric Cancer （Herceptin resistance or refractory) Phase 2 study (pivotal) (JP/Korea)			Study initiation		
U3-1402	EGFRm NSCLC Phase 1 study			Study initiation		
DS-5141	Duchenne Muscular Dystrophy Phase 1/2 study (JP)	SAKIGAKE			TLR	

Red: Update

*TLR: Top Line Results

Major R&D Pipeline

As of July 2017

Daiichi-Sankyo

Therapeutic area	Phase 1	Phase 2	Phase 3	Application
Oncology	■ DS-3032 (US/JP) (MDM2 inhibitor) ■ PLX7486 (US) (FMS / TRK inhibitor) ■ PLX8394 (US) (BRAF inhibitor) ■ DS-6051 (US/JP) (NTRK/ROS1 inhibitor) ■ PLX9486 (US) (KIT inhibitor) ■ DS-3201 (JP/US) (EZH1/2 inhibitor) ■ PLX73086 (US) (CSF-1R inhibitor) ■ PLX51107 (US) (BRD4 inhibitor) ■ DS-8273 (US) (Anti-DR5 antibody) ■ DS-8201 (JP/US) (anti-HER2 ADC) ■ DS-1123 (JP) (Anti-FGFR2 antibody) ■ U3-1402 (JP) (Anti-HER3 ADC) ■ DS-1001 (JP) (IDH1m inhibitor)	■ Patritumab (EU) (U3-1287 / Anti-HER3 antibody) ■ Pexidartinib (US) (PLX3397 / Glioblastoma / CSF-1R/KIT/FLT3-ITD inhibitor) ■ DS-1647 (JP) (Glioblastoma / **G47Δ virus**) ■ Quizartinib (JP) (AC220 / AML-2nd / FLT3-ITD inhibitor)	■ Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody) ■ Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody) ■ Vemurafenib (US/EU) (PLX4032 / Melanoma Adjuvant / BRAF inhibitor) ■ Quizartinib (US/EU/Asia) (AC220 / AML-2nd / FLT3-ITD inhibitor) ■ Quizartinib (US/EU/Asia) (AC220 / AML-1st / FLT3-ITD inhibitor) ■ Pexidartinib (US/EU) (PLX3397 / TGCT / CSF-1R/KIT/FLT3-ITD inhibitor)	
Cardiovascular-Metabolics	■ DS-1040 (US/EU/JP) (Acute ischemic stroke / TAFIa inhibitor) ■ DS-2330 (Hyperphosphatemia) ■ DS-9231/TS23 (Thrombosis / **α2**-PI inactivating antibody)	■ Esaxerenone (JP) (CS-3150 / DM nephropathy / MR antagonist)	■ Edoxaban (JP) (DU-176b / AF / FXa inhibitor) ■ Prasugrel (JP) (CS-747 / Ischemic stroke / Anti-platelet agent) ■ Esaxerenone (JP) (CS-3150 / Hypertension / MR antagonist)	■ Edoxaban (ASCA etc.) (DU-176b / AF / FXa inhibitor) ■ Edoxaban (ASCA etc.) (DU-176b / VTE / FXa inhibitor)
Others	■ DS-1971 (Chronic pain) ■ DS-1501 (US) (Osteoporosis / Anti-Siglec-15 antibody) ■ DS-7080 (US) (AMD / Angiogenesis inhibitor) ■ DS-2969 (US) (*Clostridium difficile* infection /GyrB inhibitor) ■ DS-5141 (JP) (DMD / ENA oligonucleotide) ■ VN-0102/JVC-001 (JP) (MMR vaccine)	■ Laninamivir (US/EU) (CS-8958 / Anti-influenza / out-licensing with Biota)	■ Mirogabalin (US/EU) (DS-**5565** / **Fibromyalgia** / **α2δ ligand**) ■ Mirogabalin (JP/Asia) (DS-**5565** / **DPNP**/ **α2δ ligand**) ■ Mirogabalin (JP/Asia) (DS-**5565** / **PHN** / **α2δ** ligand) ■ VN-0105 (JP) (DPT-IPV / Hib vaccine) ■ Laninamivir (JP) (CS-8958 / Anti-influenza / nebulizer)	■ Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid **μ**-receptor agonist) <Injection> ■ CL-108 (US) (Acute pain / Opioid **μ**-receptor agonist) ■ Intradermal Seasonal Influenza Vaccine (JP) (VN-100 / prefilled i.d. vaccine for seasonal flu) ■ VN-0107/MEDI3250 (JP) (Nasal spray flu vaccine)

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1126

Email: DaiichiSankyoIR@daiichisankyo.co.jp